Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases
Bill Would Remove Financial Penalties for Participating in Research Studies
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance